Genmab A/S Reduces Share Capital by Cancelling Treasury Shares Following Buyback

summarizeSummary

Genmab's Annual General Meeting approved the cancellation of treasury shares, formally reducing its share capital after completing an $89 million buyback program.

check_boxKey Events

• Share Capital Reduction Approved

  Shareholders approved the reduction of the company's share capital by nominally DKK 1,900,000 through the cancellation of treasury shares.

• Formalizes Prior Buyback

  This action follows the completion of the company's $89 million share buyback program, announced on March 16, 2026, and formally reduces the number of outstanding shares.

• Routine AGM Approvals

  The Annual Report for 2025 and the 2025 Compensation Report were approved, and the Board of Directors and Executive Management were discharged. Six board members and the auditor were re-elected.

auto_awesomeAnalysis

The company's Annual General Meeting approved a proposal to reduce share capital by cancelling treasury shares. This action formalizes the reduction in outstanding shares resulting from the recently completed $89 million share buyback program, enhancing shareholder value by increasing earnings per share. This move demonstrates a commitment to returning capital to shareholders and optimizing the capital structure.